News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Sarepta Therapeutics, Inc.
NEWS
JOBS
IN THE PRESS
NEWS
Policy
Sarepta Rockets After the FDA Delays Ruling on DMD Drug
May 25, 2016
·
4 min read
Bio NC
Sarepta Who? This DMD Drugmaker Might be a Better Buy for Investors
May 20, 2016
·
3 min read
FDA
Betting Intensifies Over Sarepta’s DMD Drug
May 6, 2016
·
1 min read
Deals
As Sarepta And Valeant Exit Hearings, Biotech Steps Into M&A
May 3, 2016
·
1 min read
Policy
Rounding Up the Experts’ Thoughts on What’s Next for Sarepta’s DMD Drug
April 27, 2016
·
3 min read
Policy
FDA Panel’s 7-6 Vote Against Sarepta’s DMD Drug Underlines Battle Between Science and Patient Advocates
April 26, 2016
·
5 min read
Policy
Sarepta’s Stock a Rollercoast Ride Prior to Today’s FDA Hearing
April 25, 2016
·
3 min read
FDA
Sarepta Craters as the FDA Releases Documents Ahead of Monday’s DMD Drug Hearing
April 21, 2016
·
3 min read
FDA
36 DMD Experts Send Letter to the FDA Urging Approval of Sarepta’s Drug
March 22, 2016
·
4 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Deals
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 31, 2020
July 31, 2020
·
2 min read
Business
Sarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020
July 29, 2020
·
1 min read
FDA
Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
July 24, 2020
·
5 min read
Genetown
Sarepta Therapeutics Launches “Rare Lessons” Program to Promote Greater Diversity and Inclusion in the Classroom and Support Awareness of Rare Diseases
July 15, 2020
·
3 min read
Business
Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase
July 2, 2020
·
8 min read
Business
Hansa Biopharma Announces Exclusive Agreement With Sarepta Therapeutics to Develop and Promote Imlifidase as Pre-treatment Ahead of Gene Therapy in Select Indications
July 2, 2020
·
6 min read
Deals
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 30, 2020
June 30, 2020
·
2 min read
Business
Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer
June 30, 2020
·
5 min read
Genetown
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
June 26, 2020
·
6 min read
Genetown
Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases
June 22, 2020
·
8 min read
